Avantor
AVTR
$7.88
+3.14%
Avantor, Inc. is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates as a key supplier and service provider through its two segments, Laboratory Solutions and Bioscience Production, offering materials & consumables, equipment & instrumentation, and specialty procurement. The current investor narrative is heavily influenced by significant operational and financial headwinds, including a sharp stock price decline of over 38% in the past year and concerns over margin pressure, as recent news highlights potential cost increases for critical medical supplies due to geopolitical disruptions in the Strait of Hormuz. This has shifted the debate towards the company's ability to navigate supply chain challenges, restore profitability, and execute a turnaround amidst a difficult market environment.…
AVTR
Avantor
$7.88
Investment Opinion: Should I buy AVTR Today?
Rating: Hold. The core thesis is that while Avantor's stock appears cheap on sales and forward earnings multiples, the severe operational headwinds, lack of profitability, and absence of a clear near-term catalyst warrant a neutral stance until evidence of a turnaround emerges.
Supporting this view are several specific data points: the stock trades at a low forward P/E of 9.33x based on estimated EPS of $1.115, and a trailing PS ratio of 1.19x. However, these valuations are countered by a negative trailing net margin of -8.09% and a stock price that has underperformed the market by 67.62 percentage points over the past year. The balance sheet shows a current ratio of 1.78 and D/E of 0.71, which are stabilizing factors but do not offset the core profitability issue.
The two biggest risks that could invalidate a Hold thesis are: 1) further margin compression from rising supply chain costs, pushing operating margins deeper into negative territory, and 2) a failure to achieve the forward EPS estimate of $1.115, revealing the forward P/E as misleadingly low. This Hold would upgrade to a Buy if the company demonstrates consecutive quarters of sequential margin improvement or provides guidance confirming the $1.115 EPS target is achievable. It would downgrade to a Sell if the price breaks decisively below the $7.26 support level on high volume. The stock is fairly valued to slightly undervalued relative to its current distressed state, but not sufficiently so to justify a Buy without operational improvement.
Sign up to view all
AVTR 12-Month Price Forecast
The outlook for AVTR is clouded with high uncertainty. The valuation is undemanding, but this is justified by severe operational challenges and a lack of positive momentum. The base case of sideways movement is most probable, as the company lacks a visible catalyst for a sharp recovery while its balance sheet provides a buffer against immediate collapse. The stance would upgrade to bullish on concrete evidence of margin stabilization for two consecutive quarters. It would turn bearish if the stock breaks $7.26 or if forward EPS estimates are cut by more than 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Avantor's 12-month outlook, with a consensus price target around $10.24 and implied upside of +29.9% versus the current price.
Average Target
$10.24
4 analysts
Implied Upside
+29.9%
vs. current price
Analyst Count
4
covering this stock
Price Range
$6 - $10
Analyst target range
Analyst coverage for Avantor is limited, with only 6 analysts providing estimates, which is indicative of a mid-cap stock with constrained institutional interest that can contribute to higher volatility and less efficient price discovery. The available data focuses on forward estimates, with an average EPS estimate of $1.115 and an average revenue estimate of $7.32 billion, but crucially, a consensus price target, recommendation distribution (Buy/Hold/Sell), and target price range are not provided in the dataset. The absence of explicit price targets and recommendations means the implied upside or downside to consensus cannot be calculated, and the signal strength from analyst sentiment—whether there is high conviction or wide disagreement—remains unknown, leaving investors with less guidance from the sell-side community.
Bulls vs Bears: AVTR Investment Factors
The evidence currently strongly favors the bear case. Avantor is in a severe operational crisis, characterized by negative profitability, a steep stock price decline, and emerging supply chain headwinds. The bull case rests on the stock being deeply oversold and trading at low sales multiples, presenting a potential value play if management can execute a successful turnaround. The single most important tension in the investment debate is whether the company's low valuation (PS of 1.19x) accurately reflects a terminal decline or an excessive discount for temporary, albeit severe, operational challenges. The resolution of this depends entirely on Avantor's ability to stem margin erosion and return to profitability, a task made more difficult by rising input costs.
Bullish
- Deeply Oversold Technicals: The stock trades at $7.96, just 9.6% above its 52-week low of $7.265 and 50% below its 52-week high of $15.93, indicating extreme pessimism is priced in. This oversold condition, coupled with a low Price-to-Sales ratio of 1.19x, suggests a potential value opportunity if the company can execute a turnaround.
- Low Valuation Multiples: The stock trades at a trailing PS ratio of 1.19x and an EV/Sales of 1.38x, which are relatively low multiples. The forward P/E of 9.33x, based on an estimated EPS of $1.115, is also inexpensive, implying the market has low expectations for future profitability.
- Manageable Balance Sheet: The company maintains a solid current ratio of 1.78, indicating sufficient short-term liquidity. Its debt-to-equity ratio of 0.71 suggests a moderate and manageable level of financial leverage, providing some stability during its operational challenges.
- Mission-Critical Industry Role: Avantor serves the biopharma and healthcare sectors, which are defensive and provide recurring demand for its mission-critical products and services. This underlying demand offers a potential base for recovery if operational issues are resolved.
Bearish
- Severe Profitability Crisis: The company is deeply unprofitable, with a trailing net margin of -8.09% and an operating margin of -3.76%. A negative ROE of -9.53% indicates it is destroying shareholder value, and a gross margin of 32.65% is being fully eroded by costs.
- Sustained Downtrend & Underperformance: The stock has declined 38.58% over the past year, massively underperforming the S&P 500's 29.04% gain, resulting in a relative strength of -67.62. The 3-month decline of 27.11% and a 1-month relative strength of -7.53 confirm the bearish momentum remains intact.
- Supply Chain & Margin Pressure: Recent news highlights that disruptions in the Strait of Hormuz are driving up petrochemical costs, which analysts warn will pressure margins for medical supplies within weeks. This directly threatens Avantor's ability to improve its already negative operating margin.
- Weak Analyst Coverage & No Price Targets: Only 6 analysts cover the stock, indicating limited institutional interest. Crucially, no consensus price target or recommendation is provided, leaving investors without a clear benchmark for valuation or upside potential, which increases uncertainty.
AVTR Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -38.58%, significantly underperforming the broader market which gained 29.04%. As of the latest close at $7.96, the price is trading near the bottom of its 52-week range, at approximately 10% above the 52-week low of $7.265 and 50% below the 52-week high of $15.93, indicating the stock is deeply oversold and may represent a value opportunity, though it carries substantial 'falling knife' risk without a clear catalyst for reversal. Recent momentum shows continued weakness, with a 3-month decline of -27.11% and a 1-month gain of only 2.45%, which is a stark divergence from the S&P 500's 9.98% gain over the same period, as indicated by the severe negative relative strength of -7.53; this suggests any recent uptick is feeble and the stock remains in a strong bearish phase with momentum severely lagging the market. Key technical support is firmly established at the 52-week low of $7.265, while resistance lies at the 52-week high of $15.93; a breakdown below $7.26 would signal a continuation of the downtrend and potentially new lows, whereas a sustained move above the recent local highs near $8.5 is needed for any bullish reversal signal. The stock's beta of 0.997 indicates its volatility is nearly identical to the market, but its massive underperformance highlights significant idiosyncratic risk rather than systematic market moves.
Beta
0.94
0.94x market volatility
Max Drawdown
-52.5%
Largest decline past year
52-Week Range
$7-$16
Price range past year
Annual Return
-41.5%
Cumulative gain past year
| Period | AVTR Return | S&P 500 |
|---|---|---|
| 1m | -7.3% | +4.6% |
| 3m | -14.4% | +8.3% |
| 6m | -31.6% | +12.5% |
| 1y | -41.5% | +25.0% |
| ytd | -31.2% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AVTR Fundamental Analysis
Revenue trajectory analysis is limited due to missing quarterly data, but forward-looking analyst estimates provide a benchmark, with an average revenue estimate of $7.32 billion for the coming period; however, the company's fundamental health is currently challenged, as evidenced by a trailing twelve-month net margin of -8.09% and an operating margin of -3.76%. The company is currently unprofitable on a net income basis, with a negative trailing EPS of -$0.068 and a negative Return on Equity (ROE) of -9.53%, indicating it is destroying shareholder value; gross margin stands at 32.65%, but this is being eroded down to negative operating and net margins, showing significant cost and operational inefficiencies that are pressuring the bottom line. Balance sheet and cash flow health show mixed signals, with a relatively strong current ratio of 1.78 indicating sufficient short-term liquidity, and a moderate debt-to-equity ratio of 0.71 suggesting a manageable leverage level; however, the negative net income and margins imply weak cash generation from operations, and the Price-to-Cash Flow ratio of 12.46, while not extreme, must be viewed in the context of the company's struggle to achieve sustainable profitability.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AVTR Overvalued?
Given the negative trailing Net Income and EPS, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 1.19x and an Enterprise Value-to-Sales (EV/Sales) of 1.38x, which are relatively low multiples that reflect the market's discount for the company's current lack of profitability and growth challenges. Peer comparison data is not available in the provided dataset, preventing a quantified assessment of whether the PS ratio represents a premium or discount to the industry; an evaluation would require the sector average to determine if the current low multiple is justified by the company's inferior profitability and negative growth trajectory, or if it presents a deep value opportunity. Historical context for valuation is also unavailable due to missing historical ratios data; without this, we cannot determine if the current PS ratio of 1.19x is near the top or bottom of the stock's own historical range, which is a critical gap in assessing whether the market's pessimistic expectations are at an extreme.
PE
-14.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's inability to generate profits. With a net margin of -8.09% and an ROE of -9.53%, Avantor is burning through shareholder equity. The 32.65% gross margin is insufficient to cover operating expenses, leading to negative operating income. While the debt-to-equity of 0.71 is manageable, the negative cash flow from operations raises questions about long-term financial sustainability without a significant improvement in cost control or pricing power.
Market & Competitive Risks are elevated due to valuation uncertainty and external shocks. The stock's beta of 0.997 indicates market-level volatility, but its 38.58% annual decline is almost entirely idiosyncratic, driven by company-specific failures. The lack of peer comparison data makes it difficult to assess if the low PS ratio of 1.19x is a discount or a fair value for a struggling company. The recent news regarding rising petrochemical costs from geopolitical disruptions presents a tangible, near-term risk to margins, potentially derailing any nascent recovery efforts before they begin.
Worst-Case Scenario involves a continuation of the current downtrend fueled by a failure to address cost structures amid rising input prices. This could lead to further earnings misses, a breach of debt covenants, or a loss of key customers, triggering a liquidity crisis. The realistic downside is significant; a retest and break below the 52-week low of $7.265 is plausible, representing a -8.7% decline from the current price of $7.96. A more severe bear case could see the stock fall towards levels implied by its max drawdown of -54.51%, which would target approximately $7.24, aligning with the recent low. An investor could realistically face a loss of 10-15% in this adverse scenario.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Continued negative profitability (net margin -8.09%) and value destruction (ROE -9.53%). 2) Macro/Supply Chain Risk: Rising input costs from geopolitical disruptions, as recently highlighted, threatening already negative margins. 3) Market Risk: Sustained bearish momentum, with the stock down 38.58% in a year and showing severe negative relative strength. 4) Liquidity/Sentiment Risk: Limited analyst coverage (only 6 analysts) and no consensus price target, leading to poor price discovery and potential for high volatility.
The 12-month forecast presents three scenarios. The base case (50% probability) sees the stock trading between $8.00 and $9.50, as struggles continue but the low valuation provides a floor. The bull case (20% probability), requiring a successful turnaround, targets $10.50-$12.00. The bear case (30% probability), triggered by worsening margins, sees a drop to $6.50-$7.30. The base case is most likely, predicated on the assumption that the company muddles through without significant improvement or further deterioration.
AVTR appears fairly valued to slightly undervalued based on its current distressed state. The trailing PS ratio of 1.19x and forward P/E of 9.33x are low multiples, but they accurately reflect the company's negative profitability and -38.58% annual price decline. Without peer data, it's hard to call it a clear discount. The valuation implies the market expects minimal growth and a prolonged struggle to achieve sustainable profits, which seems a reasonable assessment given the -8.09% net margin.
AVTR is not a good buy for most investors at this time. While the forward P/E of 9.33x and PS ratio of 1.19x appear cheap, they are offset by a severe lack of profitability, with a net margin of -8.09% and negative ROE. The stock has also dramatically underperformed the market. It could be a speculative buy only for deep-value, high-risk investors who have conviction in a multi-year turnaround and can tolerate further downside, potentially to the $7.26 support level.
AVTR is unsuitable for short-term trading due to its negative momentum, high volatility within a downtrend, and lack of near-term catalysts. It is only appropriate for a long-term, speculative investment horizon of 3-5 years, allowing time for a potential operational turnaround to materialize. The stock pays no dividend, and its beta of 0.997 indicates market-correlated volatility, but its idiosyncratic risks dominate. Investors should be prepared to hold through significant uncertainty and potential further downside.